Beitrag

03.06.2022

Dr. Teresa Amaral receives Conquer Cancer Merit Award 2022

Adjuvant therapy with checkpoint inhibitors, such as PD-1 inhibitors, and targeted therapy with BRAF/MEK inhibitors are used to treat skin cancer and are designed to block cancer cell signaling pathways and thus inhibit growth. However, not every patient benefits from these therapies. That's why Dr. Amaral and her team have been studying which patients are better suited for the use of these therapies, especially in the early stages of the disease. In collaboration with SkylineDx, they have evaluated an assay that may be relevant to these patients by identifying those at higher risk for recurrence.

We sincerely congratulate them on the award!

About the Award
The Merit Award program was established in 1995 by ASCO (American Society of Clinical Oncology) to recognize high-quality abstracts submitted by oncology researchers. These oncology experts are recognized for their respective fields and research advances in cancer treatment.